Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
Prohibited at all times under the 2026 S4.3 activin A-neutralizing antibody family; non-Specified. Coverage is by the family, not a separately printed drug name. [1] [2]
S4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulation
Garetosmab is an activin A-binding monoclonal antibody. The August 2026 US Pasatru label describes intravenous treatment to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva. [2]
- This is the checked US label, not a worldwide authorization or availability inventory.
Selected health warnings
The label contraindicates pregnancy and warns about fetal harm, skin and soft-tissue infections, and nosebleeds, including serious cases. Its clinical benefit addresses a rare genetic disorder; it is not evidence supporting muscle enhancement in healthy people. [2]
- The full label and clinician assessment remain necessary; listed risks are not exhaustive.
What remains uncertain
- No product-specific supplement-contamination pathway was established in this review; a medicine label does not establish contamination prevalence.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- PASATRU garetosmab-grts US prescribing information ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.